UK AD-SMART platform trial speeds Alzheimer disease treatment discovery by testing multiple repurposed drugs at once across NHS sites, aiming to protect memory and quality of life.
|Articles|May 15, 2019
- Psychiatric Times Vol 36, Issue 5
- Volume 36
- Issue 5
Conflict of Interest Form
Author(s)Richard M. Berlin, MD
They ask me to sign the moment before my poetry reading and I comply...
Advertisement
They ask me to sign
the moment before
my poetry reading
and I comply,
though I don’t let on
my conflicts are
my greatest interest-
how I profit from sickness,
the way I can be both
detached and concerned,
that my most inspired device
is to marry psychiatry’s science,
without conflict,
to the poetry of healing.
Articles in this issue
over 7 years ago
Introduction: Meeting Our Personal and Professional Goalsover 7 years ago
Locum Psychiatric Practice: Unexpected, Unheralded Benefitsover 7 years ago
The Role of Social Media in Private Practiceover 7 years ago
Disability: Overview of Concepts Psychiatrists Need to Knowover 7 years ago
Introduction to Immunotherapy of Malignancies for Psychiatristsover 7 years ago
Looking for AmericaAdvertisement
Related to this article
When an antidepressant seems to stop working, the patient’s deterioration is real. The explanation may be less certain.
The evidence points toward an overall protective effect in adult cohorts and no increase in completed suicide in younger populations.
A psychiatry resident and APA Diversity Leadership Fellow explains how social history, open talk about stigma, and bilingual videos can widen access to care.
Phase 2 data show RAP-219 eases acute bipolar mania with significant YMRS gains and encouraging tolerability, setting the stage for FDA talks and phase 3 plans.
Explore evolving ethical challenges of long-acting injectable antipsychotics, weighing relapse prevention against coercion, stigma, incentives, and racial equity in clinical practice.
Neurocrine launches a phase 2 trial of once-daily NBI-'567, testing a selective muscarinic agonist to boost cognition in mild to moderate Alzheimer disease.
Review finds ADHD drugs may ease perimenopause brain fog and improve daily focus, but objective cognition gains remain unclear; larger safety and efficacy studies needed.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Psych Consult: TSH Testing in New-Onset Depression. An Endocrinologist’s Guidance for Psychiatrists
2
ADHD Medications for Managing Menopausal Brain Fog: Improvements in Subjective Executive Function
3
New Phase 2 Data on Bezisterim for the Treatment of Long COVID
4
What Do Patient-Level Studies Tell Us About Antidepressants and Suicide Risk?
5